Continuous viral inactivation at low pH value in antibody manufacturing

被引:48
作者
Klutz, Stephan [1 ]
Lobedann, Martin [1 ]
Bramsiepe, Christian [1 ]
Schembecker, Gerhard [2 ]
机构
[1] Invite GmbH, Chempk Leverkusen,Bldg W32, D-51373 Leverkusen, Germany
[2] TU Dortmund Univ, BCI, Plant & Proc Design, D-44227 Dortmund, Germany
关键词
Viral inactivation; Continuous processing; Monoclonal antibody; Coiled flow inverter; Design methodology; RESIDENCE TIME DISTRIBUTION; PERFUSION CULTURE; PROCESS INTENSIFICATION; MONOCLONAL-ANTIBODIES; SMALL-SCALE; FLOW; TECHNOLOGY; INDUSTRY;
D O I
10.1016/j.cep.2016.01.002
中图分类号
TE [石油、天然气工业]; TK [能源与动力工程];
学科分类号
0807 ; 0820 ;
摘要
Due to the evolving biopharmaceutical market, small scale and flexible production processes for continuous antibody manufacturing become more important. Consequently, various continuously operated processing steps like perfusion fermentation or continuous chromatography have been developed. However, no continuously operated viral inactivation at low pH value is available so far. In this article, the coiled flow inverter (CFI) is identified as a suitable reactor for this application and two different design approaches are presented. The logarithmic reduction value (LRV) approach targets at the same LRV in the continuous viral inactivation when compared to current batch operation. The minimum residence time (MRT) approach guarantees a residence time for all molecules entering the continuous viral inactivation of at least the inactivation time of the batch inactivation step. The viral reduction value and the monomer loss during inactivation are characterized for each design approach. Moreover, a linear regression model is developed, which predicts the Bodenstein number as a function of two CFI design parameters under defined boundary conditions. This model allows designing the CFI according to the inactivation time and the chosen design approach. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:88 / 101
页数:14
相关论文
共 35 条
[1]   What's fueling the biotech engine-2010 to 2011 [J].
Aggarwal, Saurabh .
NATURE BIOTECHNOLOGY, 2011, 29 (12) :1083-1089
[2]  
Anicetti V, 2009, BIO PROCESS INT, V7, P4
[3]   Future Production Concepts in the Chemical Industry: Modular - Small-Scale - Continuous [J].
Bieringer, Thomas ;
Buchholz, Sigurd ;
Kockmann, Norbert .
CHEMICAL ENGINEERING & TECHNOLOGY, 2013, 36 (06) :900-910
[4]  
Bisschops M, 2009, BIOPROCESS INT, P18
[5]  
Bonham-Carter J., 2011, BIOPROCESS INT, V9, P24, DOI DOI 10.12665/J131.LANGER
[6]   Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins [J].
Brorson, K ;
Sherrie, K ;
Lee, K ;
Hamilton, E ;
Stein, K ;
Xu, Y .
BIOTECHNOLOGY AND BIOENGINEERING, 2003, 82 (03) :321-329
[7]   Recent advances in technology supporting biopharmaceutical production from mammalian cells [J].
Butler, M. ;
Meneses-Acosta, A. .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2012, 96 (04) :885-894
[8]   FORMULATION CONCERNS OF PROTEIN DRUGS [J].
CHEN, T .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1992, 18 (11-12) :1311-1354
[9]  
CMC Biotech Working Group Study Guide, 2009, A-Mab: A Case Study in Bioprocess Development
[10]  
FDA Q5A Guidance Document, 1998, GUIDANCE IND Q5A VIR, V63, P1